Posttransplant bone disease: a case illustrating dramatic improvements in bone density with vitamin D replacement therapy.
Although bisphosponates are proposed as first-line treatment for posttransplant bone disease they are not optimal in all situations. A kidney transplant recipient developed hypercalcemia from mobilization of extraskeletal calcium. He had low serum parathyroid hormone and vitamin D; high calcium excretion; and normal calcium intake. Bone biopsy revealed severe osteomalacia. Bisphosphonates, used in the early treatment of acute hypercalcemia, were not indicated to treat osteomalacia. However, over several months serum calcium declined sufficiently to allow treatment of the bone disease with oral calcitriol. Dual-energy radiographic absorptiometry over the next 2 years documented dramatic improvements in bone density (percent of young-normal controls) : from 63 to 85%, at the lumbar spine; from 38 to 67%, at the femoral neck. This response to treatment could not have been achieved with an antiresorptive strategy. Optimal management of posttransplant bone disease requires a diagnostic approach, which considers all plausible contributing factors.
Dhingra
R K
RK
Nephrology Division, University of Michigan Medical Center, 315 W. Huron, Ann Arbor, MI 48103-4262.
Sprague
S M
SM
Ojo
A O
AO
Leavey
S F
SF
D015502:Absorptiometry, Photon; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D002117:Calcitriol / Q000627:therapeutic use*; D002120:Calcium Channel Agonists / Q000627:therapeutic use*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D010018:Osteomalacia / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D014808:Vitamin D Deficiency / Q000188:drug therapy*
D002120:Calcium Channel Agonists; D002117:Calcitriol